FDA of­fers ‘break­through’ sta­tus for a HER2xHER2 bis­pe­cif­ic at the top of Zymeworks’ pipeline

Van­cou­ver-based Zymeworks just got a leg up in its quest to win an ac­cel­er­at­ed ap­proval for their lead drug: a HER2-tar­get­ed bis­pe­cif­ic dubbed zanidatam­ab in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER